The Scientific World Journal

The Scientific World Journal / 2006 / Article

Research Article | Open Access

Volume 6 |Article ID 257151 | https://doi.org/10.1100/tsw.2006.247

Ahmad M. Kamal, Richard P.G. Hayhoe, Anbalakan Paramasivam, Dianne Cooper, Roderick J. Flower, Egle Solito, Mauro Perretti, "Antiflammin-2 Activates the Human Formyl-Peptide Receptor Like 1", The Scientific World Journal, vol. 6, Article ID 257151, 10 pages, 2006. https://doi.org/10.1100/tsw.2006.247

Antiflammin-2 Activates the Human Formyl-Peptide Receptor Like 1

Academic Editor: John L. Wallace
Received29 Sep 2006
Revised16 Oct 2006
Accepted17 Oct 2006

Abstract

The anti-inflammatory actions of the nonapeptide antiflammin-2, identified by homology with uteroglobin and annexin-A1 sequences, have been described in some detail, yet its mechanisms of action remain elusive. Since recent data indicate an involvement of the formyl peptide receptor (FPR)-like 1 (or FPRL-1) in the effects of annexin-A1, we have tested here the effect of antiflammin-2 with respect to this receptor family. Using HEK-293 cells expressing either human FPR and FPRL-1, and an annexin-A1 peptide as tracer ([125I-Tyr]-Ac2-26), we found that antiflammin-2 competed for binding only at FPRL-1, and not FPR, with an approximate EC50 of 1 μM. In line with data produced for the full-length protein, genuine receptor activation by antiflammin-2 was confirmed by rapid phosphorylation of extracellular-regulated kinase 1 and 2. Finally, study of the neutrophil interaction with activated endothelium under flow demonstrated an inhibitory effect of antiflammin-2, thus providing functional support to a role for the antiflammin-2/FPRL-1 anti-inflammatory axis.


More related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Order printed copiesOrder
Views247
Downloads568
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.